Crinetics Pharmaceuticals, a clinical-stage biotechnology company focused on developing innovative therapeutics for rare endocrine diseases and endocrine-related tumors, has announced promising results from two separate studies evaluating the efficacy of their once-daily oral drug, paltusotine. In the Phase 3 PATHFNDR-2 study conducted in patients with acromegaly, paltusotine demonstrated significant effectiveness, achieving the primary and all secondary endpoints. Furthermore, the company had previously reported positive findings from an ongoing Phase 2 study investigating paltusotine for the treatment of carcinoid syndrome.
Acromegaly is a rare hormonal disorder caused by the excessive production of growth hormone (GH), which leads to the overgrowth of body tissues. Characterized by abnormal growth in certain body parts, such as the hands, feet, and face, acromegaly also results in various metabolic abnormalities and co-morbidities. One of the primary treatment s for acromegaly is to normalize the levels of insulin-like growth factor 1 (IGF-1), a protein strongly linked to GH secretion and the overgrowth experienced in acromegalic patients. Crinetics’ paltusotine has shown superior efficacy in achieving this goal, with 56% of participants achieving IGF-1 levels of 1.0 times the upper limit of normal (ULN) compared to only 5% of patients on placebo (p
Comments